Literature DB >> 14644823

Seventy-five microgram desogestrel minipill, a new perspective in estrogen-free contraception.

Giuseppe Benagiano1, Francesco Maria Primiero.   

Abstract

Progestin-only minipills have been available for over three decades, yet their use has been limited, because of a documented lower efficacy when compared to pills that combine estrogen and progestin. The availability of a new low-dose progestin-only minipill containing 75 microg desogestrel (DSG) offers a new perspective, since, in a large multicenter study, this minipill gave a crude Pearl index of 0.41 and an adjusted one of 0.14, which is comparable to indices found in clinical trials of oral contraceptives. This minipill also allows for a 12-hour tolerance time in taking the pill. The high effectiveness of the DSG minipill is attributable to an almost constant inhibition of ovulation, as shown by the absence of elevated progesterone circulating levels and inhibition of follicular growth in the vast majority of cycles studied. Since irregular bleeding patterns are observed with all minipills, patterns experienced with DSG 75 microg have been compared to those obtained with levonogestrel 30 microg. As expected, the more pronounced ovarian inhibition produced wider bleeding variability with DSG, but also less bleeding overall. The DSG minipill is suitable for lactating women and represents a valuable addition to oral contraception.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14644823     DOI: 10.1196/annals.1290.019

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  4 in total

1.  Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.

Authors:  Claudio N Soares; Michael E Thase; Anita Clayton; Christine J Guico-Pabia; Kristen Focht; Qin Jiang; Susan G Kornstein; Phillip T Ninan; Cecelia P Kane
Journal:  CNS Drugs       Date:  2011-03       Impact factor: 5.749

2.  Randomized, Crossover and Single-Dose Bioquivalence Study of Two Oral Desogestrel Formulations (Film-Coated Tablets of 75 μg) in Healthy Female Volunteers.

Authors:  María Ángeles Pena; Emilio Sanz; Silvia Francisco; Ainhara Alonso; Zurine Abajo; Izaskun Felipe; Jaume Pascual; Digna Tost; Sandra Bailac
Journal:  Sci Pharm       Date:  2012-03-01

Review 3.  Medical management of heavy menstrual bleeding.

Authors:  Jacqueline A Maybin; Hilary O D Critchley
Journal:  Womens Health (Lond)       Date:  2015-12-23

Review 4.  Heavy menstrual bleeding diagnosis and medical management.

Authors:  Intira Sriprasert; Tarita Pakrashi; Thomas Kimble; David F Archer
Journal:  Contracept Reprod Med       Date:  2017-07-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.